Navigation Links
Rhythm Names Lex Van der Ploeg Chief Scientific Officer
Date:11/30/2011

BOSTON, Nov. 30, 2011 /PRNewswire/ -- Rhythm announced today that Lex Van der Ploeg, PhD, has joined the company as Chief Scientific Officer. Dr. Van der Ploeg brings to Rhythm more than 25 years of drug development expertise in obesity, metabolic diseases, and other therapeutic areas.

"Lex has considerable experience with the biology and genetics of the metabolic pathways we are targeting with our ghrelin and melanocortin 4 receptor clinical programs," said Keith Gottesdiener, MD, CEO of Rhythm. "He led obesity metabolic research at Merck that put 10 product candidates into clinical development, leveraging research that included the discovery of the ghrelin receptor and pioneering R&D discoveries related to MC4R and other metabolic pathways. We are very happy to have him with us."

Dr. Van der Ploeg's experience includes 17 years at Merck Research Laboratories (MRL), where his positions included Vice President, Basic Research and Site Head at MRL Boston, Site Head at MRL San Diego, and Head, Obesity Research. In these R&D leadership roles, Dr. Van der Ploeg directed drug development programs in metabolism, oncology, and neurodegenerative diseases. After Merck, he focused on personalized medicine as Head, R&D at Abraxis Health, which was ultimately acquired by Celgene. Dr. Van der Ploeg received an MS in Biochemistry and Enzymology from the University of Amsterdam and a PhD in Biochemistry/Enzymology/Genetics from the University of Amsterdam/Netherlands Cancer Institute.

"Rhythm's metabolic peptide programs are built on a strong preclinical foundation, targeting mechanisms that have considerable potential to make important drugs," said Dr. Van der Ploeg. "I am very pleased to join this excellent team to help develop this exciting portfolio of drug candidates for obesity, diabetes, and GI metabolic disorders."

About Rhythm Pharmaceuticals (www.rhythmtx.com)

Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm is developing the ghrelin peptide agonist, RM-131, for the treatment of diabetic gastroparesis and the MC4R peptide agonist, RM-493, for obesity and diabetes. Rhythm investors include MPM Capital, New Enterprise Associates, and Third Rock Ventures. The company is based in Boston, Massachusetts.

Contact:
Bart Henderson
President
(857) 264-4281
bhenderson@rhythmtx.com


'/>"/>
SOURCE Rhythm
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
2. Guam rhino beetles got rhythm
3. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
4. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
5. Biosense Webster Reinforces its Leadership Position in the Electrophysiology Market at Heart Rhythm 2010
6. Rhythms RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
7. Dangerous arrhythmia analyzed in a heartbeat
8. Differing structures underlie differing brain rhythms in healthy and ill
9. Rhythm Names Keith M. Gottesdiener Chief Executive Officer
10. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
11. Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017  In Atlanta, it seems everyone has ... culture intertwine to create an expressive and dynamic community unlike ... energy and contribute to it. With their ... Fairies seeks to carry on that tradition with a ... Atlanta salon is the newest of 13 nationwide ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of ... Assay from Salimetrics’ SalivaLab , the relationship between insulin and other relevant ...
Breaking Biology Technology:
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
Breaking Biology News(10 mins):